Trials / Withdrawn
WithdrawnNCT04388202
Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram
Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram (LEAP-SE): A Multicenter, Randomized, Blinded Outcome Study of EEG-guided Treatment With Sertraline Versus Escitalopram in Adults With Major Depressive Disorder
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Alto Neuroscience · Industry
- Sex
- All
- Age
- 22 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The LEAP-SE study will be conducted to validate the utility of EEG biomarkers as an aid to antidepressant treatment selection in adults with MDD.
Detailed description
The LEAP-SE study is an 8-week, multicenter, randomized, blinded study to evaluate the performance of EEG-based biomarkers in predicting treatment outcome. Study participants will be randomized in a 1:1 ratio to receive either sertraline or escitalopram and followed for 8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sertraline | FDA approved antidepressant |
| DRUG | Escitalopram | FDA approved antidepressant |
Timeline
- Start date
- 2020-10-15
- Primary completion
- 2023-05-30
- Completion
- 2023-05-30
- First posted
- 2020-05-14
- Last updated
- 2020-10-19
Source: ClinicalTrials.gov record NCT04388202. Inclusion in this directory is not an endorsement.